PAREXEL introduces new version of Regulatory Information Management platform

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight® 6.0. The LIQUENT InSight platform supports the entire regulatory product lifecycle, from early planning of registration targets through product retirement, with robust submission planning, publishing, viewing and registration management capabilities.

While biopharmaceutical companies and the patients who can benefit from new drugs are located throughout the world, there is no single international regulatory body to review and approve new medicine applications. For new and innovative medicines to successfully reach patients and maintain regulatory compliance throughout the product lifecycle, biopharmaceutical companies must navigate the complex, global regulatory and region-specific regulations.

"LIQUENT InSight 6.0 simplifies navigation of the global regulatory environment and provides the submission and registration management tools needed to more quickly bring treatments to market and effectively maintain them throughout their lifespan," said Xavier Flinois, President, PAREXEL Informatics. "As an essential part of the drug development journey, the LIQUENT InSight platform centralizes a company's regulatory information to drive standardization, improve collaboration, and helps to ensure compliance, eliminate waste, reduce costs, and increase efficiencies so more patients can quickly and safely receive the treatments they need."

Enhancements to the LIQUENT InSight platform include:

  • Business Intelligence: added robust analytics to enhance reporting capabilities
  • Usability: simplified interface designed by usability experts provide an intuitive experience to all levels of InSight users
  • Compliance: updated data model and architecture helps to ensure processes, output and work product compliance with standards such as XEVMPD and the upcoming IDMP mandate
  • Interoperability: revamped interoperability web services features that help systems interact and communicate with each other

Since the market introduction of LIQUENT InSight in 2004, more than 40 companies (including 14 of the top 20 pharmaceutical companies) have selected the LIQUENT InSight platform as their single source of regulatory information. PAREXEL's RIM technologies can also be coupled with comprehensive professional services from PAREXEL® Consulting, which provides a full complement of Regulatory Outsourcing Services to help companies meet the demands of today's complex and changing regulatory environment. LIQUENT InSight 6.0 will also be available through the Perceptive® Partner Program.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Parexel. (2019, June 20). PAREXEL introduces new version of Regulatory Information Management platform. News-Medical. Retrieved on July 22, 2024 from

  • MLA

    Parexel. "PAREXEL introduces new version of Regulatory Information Management platform". News-Medical. 22 July 2024. <>.

  • Chicago

    Parexel. "PAREXEL introduces new version of Regulatory Information Management platform". News-Medical. (accessed July 22, 2024).

  • Harvard

    Parexel. 2019. PAREXEL introduces new version of Regulatory Information Management platform. News-Medical, viewed 22 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PAREXEL International expands clinical trial site alliance network